Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverONCO
HealthcareNCMUSD

Onconetix, Inc.

$00123456789.0012345678900123456789-9.3%
52w low $0.59$209.50 52w high
Market data · last updated 1d ago
Market data
Market cap
$2.77M
52w range
$0.59 - $209.50
Beta
2.68
Sector
Healthcare
Data quality
92/100
Valuation
P/E ratio
0.0x
fair value estimate
$1.65
Margin of safety
+121.7%
Quality & efficiency
Moat score
35/100
Return on equity
-123.3%
Debt / equity
0.02
Growth & analysts
Revenue growth
-78.9%
Run the 10-point checklist before you buy How these numbers are made

About Onconetix, Inc.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Valuation

ValueGrowthProfitHealthIncome42QUALITY
Overall Rating
51
Moderate quality
Moderate quality

Derived from filed metrics · High confidence (92% of the inputs available)

Moat Score35
Fair value estimate
$1.65+121.7% upside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$2.77M
P/E Ratio
0.0
Dividend Yield
0.00%
Revenue Growth
-78.9%
Profit Margin
0.0%
ROE
-123.3%
Debt / Equity
0.02
Beta
2.68
ValueBeaten Down

Statistics

Similar Stocks · Healthcare

Latest News · ONCO